Application of monoclonal antibodies for endothelin to hypertensive research

Yoshihiko Saito, Kazuwa Nakao, Masashi Mukoyama, Gotaro Shirakami, Hiroshi Itoh, Takayuki Yamada, Hiroshi Arai, Kiminori Hosoda, Shin Ichi Suga, Michihisa Jougasaki, Yoshihiro Ogawa, Shigeyuki Nakajima, Motohiko Ueda, Hiroo Imura

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

We developed six kinds of monoclonal antibodies against endothelin (ET)-l recognizing different epitopes with high affinities (5x1010 M-1 to 5x1O11 M-1). Using these monoclonal antibodies, we developed radioimmunoassays for ET-1 with different specificities. Crossreactivities with ET-2 ranged from 80% to 100%, and those with ET-3 ranged from 3% to 60%. Patients with essential hypertension (si=20) showed a significant elevation in the plasma ET-l-LI level compared with age-matched control subjects (n = 12) (30.1 ±1.4 pg/ml versus 18.5±0.9 pg/ml, p<0.01). The plasma ET-l-LI level in hypertensive patients in stages II and 111 (World Health Organization classification) was significantly higher than that in those patients in stage I. There was no significant correlation between the plasma ET-l-LI level and systolic blood pressure (r=0.11), diastolic blood pressure (r=-0.13), or age (r=0.24) in all patients studied who had essential hypertension. In the neutralization experiment, monoclonal antibodies attenuated ET-l-induced contraction of rat aortic rings and the pressor action of ET-1 in pithed rats in vivo. The present study demonstrates the elevated plasma ET-l-LI level in patients with essential hypertension. Monoclonal antibodies developed in this study can become powerful tools to investigate the pathophysiological significance of ET in essential hypertension.

Original languageEnglish
Pages (from-to)734-738
Number of pages5
JournalHypertension
Volume15
Issue number6
DOIs
Publication statusPublished - Jan 1 1990
Externally publishedYes

Fingerprint

Endothelins
Monoclonal Antibodies
Research
Blood Pressure
Endothelin-1
Endothelin-2
Endothelin-3
Radioimmunoassay
Epitopes
Essential Hypertension

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Saito, Y., Nakao, K., Mukoyama, M., Shirakami, G., Itoh, H., Yamada, T., ... Imura, H. (1990). Application of monoclonal antibodies for endothelin to hypertensive research. Hypertension, 15(6), 734-738. https://doi.org/10.1161/01.HYP.15.6.734

Application of monoclonal antibodies for endothelin to hypertensive research. / Saito, Yoshihiko; Nakao, Kazuwa; Mukoyama, Masashi; Shirakami, Gotaro; Itoh, Hiroshi; Yamada, Takayuki; Arai, Hiroshi; Hosoda, Kiminori; Suga, Shin Ichi; Jougasaki, Michihisa; Ogawa, Yoshihiro; Nakajima, Shigeyuki; Ueda, Motohiko; Imura, Hiroo.

In: Hypertension, Vol. 15, No. 6, 01.01.1990, p. 734-738.

Research output: Contribution to journalArticle

Saito, Y, Nakao, K, Mukoyama, M, Shirakami, G, Itoh, H, Yamada, T, Arai, H, Hosoda, K, Suga, SI, Jougasaki, M, Ogawa, Y, Nakajima, S, Ueda, M & Imura, H 1990, 'Application of monoclonal antibodies for endothelin to hypertensive research', Hypertension, vol. 15, no. 6, pp. 734-738. https://doi.org/10.1161/01.HYP.15.6.734
Saito Y, Nakao K, Mukoyama M, Shirakami G, Itoh H, Yamada T et al. Application of monoclonal antibodies for endothelin to hypertensive research. Hypertension. 1990 Jan 1;15(6):734-738. https://doi.org/10.1161/01.HYP.15.6.734
Saito, Yoshihiko ; Nakao, Kazuwa ; Mukoyama, Masashi ; Shirakami, Gotaro ; Itoh, Hiroshi ; Yamada, Takayuki ; Arai, Hiroshi ; Hosoda, Kiminori ; Suga, Shin Ichi ; Jougasaki, Michihisa ; Ogawa, Yoshihiro ; Nakajima, Shigeyuki ; Ueda, Motohiko ; Imura, Hiroo. / Application of monoclonal antibodies for endothelin to hypertensive research. In: Hypertension. 1990 ; Vol. 15, No. 6. pp. 734-738.
@article{f0db198752264a41847ecffc407d47e5,
title = "Application of monoclonal antibodies for endothelin to hypertensive research",
abstract = "We developed six kinds of monoclonal antibodies against endothelin (ET)-l recognizing different epitopes with high affinities (5x1010 M-1 to 5x1O11 M-1). Using these monoclonal antibodies, we developed radioimmunoassays for ET-1 with different specificities. Crossreactivities with ET-2 ranged from 80{\%} to 100{\%}, and those with ET-3 ranged from 3{\%} to 60{\%}. Patients with essential hypertension (si=20) showed a significant elevation in the plasma ET-l-LI level compared with age-matched control subjects (n = 12) (30.1 ±1.4 pg/ml versus 18.5±0.9 pg/ml, p<0.01). The plasma ET-l-LI level in hypertensive patients in stages II and 111 (World Health Organization classification) was significantly higher than that in those patients in stage I. There was no significant correlation between the plasma ET-l-LI level and systolic blood pressure (r=0.11), diastolic blood pressure (r=-0.13), or age (r=0.24) in all patients studied who had essential hypertension. In the neutralization experiment, monoclonal antibodies attenuated ET-l-induced contraction of rat aortic rings and the pressor action of ET-1 in pithed rats in vivo. The present study demonstrates the elevated plasma ET-l-LI level in patients with essential hypertension. Monoclonal antibodies developed in this study can become powerful tools to investigate the pathophysiological significance of ET in essential hypertension.",
author = "Yoshihiko Saito and Kazuwa Nakao and Masashi Mukoyama and Gotaro Shirakami and Hiroshi Itoh and Takayuki Yamada and Hiroshi Arai and Kiminori Hosoda and Suga, {Shin Ichi} and Michihisa Jougasaki and Yoshihiro Ogawa and Shigeyuki Nakajima and Motohiko Ueda and Hiroo Imura",
year = "1990",
month = "1",
day = "1",
doi = "10.1161/01.HYP.15.6.734",
language = "English",
volume = "15",
pages = "734--738",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Application of monoclonal antibodies for endothelin to hypertensive research

AU - Saito, Yoshihiko

AU - Nakao, Kazuwa

AU - Mukoyama, Masashi

AU - Shirakami, Gotaro

AU - Itoh, Hiroshi

AU - Yamada, Takayuki

AU - Arai, Hiroshi

AU - Hosoda, Kiminori

AU - Suga, Shin Ichi

AU - Jougasaki, Michihisa

AU - Ogawa, Yoshihiro

AU - Nakajima, Shigeyuki

AU - Ueda, Motohiko

AU - Imura, Hiroo

PY - 1990/1/1

Y1 - 1990/1/1

N2 - We developed six kinds of monoclonal antibodies against endothelin (ET)-l recognizing different epitopes with high affinities (5x1010 M-1 to 5x1O11 M-1). Using these monoclonal antibodies, we developed radioimmunoassays for ET-1 with different specificities. Crossreactivities with ET-2 ranged from 80% to 100%, and those with ET-3 ranged from 3% to 60%. Patients with essential hypertension (si=20) showed a significant elevation in the plasma ET-l-LI level compared with age-matched control subjects (n = 12) (30.1 ±1.4 pg/ml versus 18.5±0.9 pg/ml, p<0.01). The plasma ET-l-LI level in hypertensive patients in stages II and 111 (World Health Organization classification) was significantly higher than that in those patients in stage I. There was no significant correlation between the plasma ET-l-LI level and systolic blood pressure (r=0.11), diastolic blood pressure (r=-0.13), or age (r=0.24) in all patients studied who had essential hypertension. In the neutralization experiment, monoclonal antibodies attenuated ET-l-induced contraction of rat aortic rings and the pressor action of ET-1 in pithed rats in vivo. The present study demonstrates the elevated plasma ET-l-LI level in patients with essential hypertension. Monoclonal antibodies developed in this study can become powerful tools to investigate the pathophysiological significance of ET in essential hypertension.

AB - We developed six kinds of monoclonal antibodies against endothelin (ET)-l recognizing different epitopes with high affinities (5x1010 M-1 to 5x1O11 M-1). Using these monoclonal antibodies, we developed radioimmunoassays for ET-1 with different specificities. Crossreactivities with ET-2 ranged from 80% to 100%, and those with ET-3 ranged from 3% to 60%. Patients with essential hypertension (si=20) showed a significant elevation in the plasma ET-l-LI level compared with age-matched control subjects (n = 12) (30.1 ±1.4 pg/ml versus 18.5±0.9 pg/ml, p<0.01). The plasma ET-l-LI level in hypertensive patients in stages II and 111 (World Health Organization classification) was significantly higher than that in those patients in stage I. There was no significant correlation between the plasma ET-l-LI level and systolic blood pressure (r=0.11), diastolic blood pressure (r=-0.13), or age (r=0.24) in all patients studied who had essential hypertension. In the neutralization experiment, monoclonal antibodies attenuated ET-l-induced contraction of rat aortic rings and the pressor action of ET-1 in pithed rats in vivo. The present study demonstrates the elevated plasma ET-l-LI level in patients with essential hypertension. Monoclonal antibodies developed in this study can become powerful tools to investigate the pathophysiological significance of ET in essential hypertension.

UR - http://www.scopus.com/inward/record.url?scp=0025314793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025314793&partnerID=8YFLogxK

U2 - 10.1161/01.HYP.15.6.734

DO - 10.1161/01.HYP.15.6.734

M3 - Article

C2 - 2190925

AN - SCOPUS:0025314793

VL - 15

SP - 734

EP - 738

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 6

ER -